OSSIO CEO Brian Verrier on orthopedic fixation market opportunities

Written by Shayna Korol | March 13, 2019 | Print  |

Orthopedic fixation company OSSIO recently secured $22 million in financing.

OSSIO CEO Brian Verrier spoke with Becker's Spine Review about the company's proprietary platform and the orthopedic fixation market.

Question: What is the market opportunity for the OSSIOfiber platform?

Brian Verrier: OSSIO is committed to transforming the orthopedic fixation market with the first credible replacement to metal fixation implants. As we move toward the commercial launch of the OSSIOfiber Bone Pin Family, we have already received incredible interest and anticipate significant product demand. The main focus will be in treating conditions in the forefoot market, where we estimate the addressable market opportunity to be approximately $1 billion. Over the course of the next three years, we will launch several additional products, which would expand our addressable markets to approximately $2.5 billion to $3 billion.

Q: What challenges and opportunities do you see in the orthopedic fixation market in 2019?

BV: Although OSSIOfiber is an extremely proprietary material platform that delivers a desired combination of strength and bio-friendliness that has not been achieved before, we fully expect competitive response. The medical device industry is one of the most dynamic and competitive environments of any industry, so we have been preparing what we need to do to drive early and strong adoption of our technology.

Beyond that, the challenges we will face are no different than any other company bringing a new technology to market. Frankly, there are more opportunities than challenges since orthopedic fixation space has not seen real transformational material innovation. This has not been from a lack of interest or effort by all of the major players, but developing a credible replacement to metal for bone fixation has been elusive. These are massive markets and it will not take us long to demonstrate that OSSIOfiber will shift early focus markets.

More articles on devices:
Earlier return to function after total knee replacement with CyMedical Orthopedics' device, study finds
Sony to showcase surgical solutions at AAOS — 5 innovations
Smith & Nephew makes $660M acquisition to strengthen wound care, orthopedics: 6 details

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies here.

Top 40 Articles from the Past 6 Months